We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$213M
Cap. Flow
-$89.6M
Cap. Flow %
-7.9%
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
32
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$43.3M
2
TERN
Terns Pharmaceuticals
TERN
+$30M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$23.4M
4
TXG icon
10x Genomics
TXG
+$18.8M
5
ELVN icon
Enliven Therapeutics
ELVN
+$16.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$44.7M
2
UTHR icon
United Therapeutics
UTHR
+$31.3M
3
HCA icon
HCA Healthcare
HCA
+$17.2M
4
BIIB icon
Biogen
BIIB
+$15.7M
5
WGS icon
GeneDx Holdings
WGS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Consumer Staples 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.69B
$17M 1.5%
826,500
+457,500
+124% +$9.57M
HUM icon
27
Humana
HUM
$43.7B
$16.6M 1.46%
44,356
-27,650
-38% -$9.34M
GSK icon
28
GSK
GSK
$104B
$16M 1.41%
415,000
+95,783
+30% +$4.03M
TMCI icon
29
Treace Medical Concepts
TMCI
$280M
$15.7M 1.39%
2,365,648
+1,020,000
+76% +$8.24M
PCVX icon
30
Vaxcyte
PCVX
$7.81B
$14M 1.23%
185,250
-22,500
-11% -$1.53M
TXG icon
31
10x Genomics
TXG
$6B
$14M 1.23%
+719,000
New +$18.8M
CGON icon
32
CG Oncology
CGON
$6.28B
$13.4M 1.18%
424,585
+206,714
+95% +$7.16M
NUVL
33
DELISTED
Nuvalent
NUVL
$13M 1.15%
171,788
+42,500
+33% +$3.02M
EOLS icon
34
Evolus
EOLS
$385M
$12.5M 1.1%
1,152,000
+992,000
+620% +$12.2M
ENTA icon
35
Enanta Pharmaceuticals
ENTA
$366M
$10.4M 0.91%
799,546
+219,000
+38% +$2.96M
ALEC icon
36
Alector
ALEC
$168M
$10.2M 0.9%
+2,239,006
New +$11.5M
KROS icon
37
Keros Therapeutics
KROS
$199M
$10.1M 0.89%
221,600
-52,000
-19% -$2.79M
TEVA icon
38
Teva Pharmaceuticals
TEVA
$40.8B
$9.53M 0.84%
586,499
-2,899,941
-83% -$44.7M
ACLX
39
DELISTED
Arcellx
ACLX
$9.42M 0.83%
170,741
+20,741
+14% +$1.13M
BDSX icon
40
Biodesix
BDSX
$220M
$9.35M 0.82%
+305,598
New +$8.73M
TNGX icon
41
Tango Therapeutics
TNGX
$4.43B
$9.01M 0.79%
1,049,895
-300,250
-22% -$2.32M
KIDS icon
42
OrthoPediatrics
KIDS
$519M
$8.9M 0.79%
+309,500
New +$9.49M
RIGL icon
43
Rigel Pharmaceuticals
RIGL
$681M
$8.58M 0.76%
1,043,697
+119,498
+13% +$1.25M
BHC icon
44
Bausch Health
BHC
$2.58B
$8.41M 0.74%
1,206,000
+536,000
+80% +$4.06M
IMUX icon
45
Immunic
IMUX
$190M
$8.1M 0.71%
729,301
– –
YMAB
46
DELISTED
Y-mAbs Therapeutics
YMAB
$7.83M 0.69%
647,982
+77,000
+13% +$1.04M
ENGN icon
47
enGene Therapeutics
ENGN
$120M
$7.54M 0.67%
800,000
– –
PHVS icon
48
Pharvaris
PHVS
$2.28B
$7.51M 0.66%
399,430
-2,471
-0.6% -$50.3K
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
$7.16M 0.63%
+509,000
New +$8.3M
DYN icon
50
Dyne Therapeutics
DYN
$4.7B
$7.09M 0.63%
+201,000
New +$5.84M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return

Soleus Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Soleus Capital Management held 116 positions worth $1.13B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Soleus Capital Management withdrew a net $89.6M in Q2 2024, closing 24 positions and reducing 25 holdings. Its most notable exit was HCA Healthcare, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Terns Pharmaceuticals worth $33.7M.

  • Soleus Capital Management's largest Q2 2024 buy was Terns Pharmaceuticals: 4,947,738 shares worth $33.7M.
  • Soleus Capital Management added most to Iovance Biotherapeutics in Q2 2024, an estimated $43.3M increase.
  • Soleus Capital Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $44.7M.
  • Soleus Capital Management fully exited HCA Healthcare in Q2 2024, selling an estimated $17.2M.
  • Soleus Capital Management's ten largest holdings make up 37% of its $1.13B portfolio in Q2 2024.
  • Soleus Capital Management opened 25 new positions and closed 24 in Q2 2024.
  • Soleus Capital Management's portfolio value fell 16% quarter-over-quarter to $1.13B.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.